A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Phase 1 Completed 12 enrolled Boehringer Ingelheim

RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the absolute bioavailability of BI 1265162 following administration of oral solution and inhaled (with and without charcoal) via Respimat.

Timeline

Start: 2019-04-23
Primary completion: 2019-12-06
Completion: 2019-12-06

Publications

Mackie A, Rascher J, Schmid M, Endriss V, Brand T, Seibold W. First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers. ERJ Open Res. 2021 Feb 1;7(1):00447-2020. doi: 10.1183/23120541.00447-2020. eCollection 2021 Jan.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 1265162	Unknown	—	—

Indications

No indication recorded.